In this regard, in vivo and in vitro data suggest that PTX3 acts as an endogenous inhibitor of complement overactivation and neovascularization in the human eye, thus holding promise as a pharmacological target for the treatment of AMD (Wang et al., 2016; Stravalaci et al., 2020). The gene discussed is PTX3; the disease is age-related macular degeneration.